Novartis Accelerates Drug Discovery with AI Cutting Timelines to Around One Year

Novartis uses AI platforms to analyze millions of chemical compounds, reporting that discovery cycles have dropped from the traditional five‑to‑ten years to roughly two years, speeding candidate selection for clinical trials across more than 200 disease targets.

Insilico CEO states AI models now enable a complete drug‑discovery workflow in about one year, a pace he says matches the fastest global benchmarks and could halve development costs, saving billions in R&D.

Bora Pharmaceuticals has signed a strategic alliance with Insilico to integrate its generative‑AI engine, leveraging cloud‑based AI infrastructure, into Bora’s pipeline, targeting oncology and metabolic diseases and planning joint trials on three AI‑designed candidates by next year.

Rentosertib, an AI‑designed inhibitor for idiopathic pulmonary fibrosis, demonstrated reversal of biological age markers in pre‑clinical studies, with six independent proteomic aging clocks confirming a statistically significant rejuvenation effect, indicating potential to enter Phase I trials within 18 months.